157 related articles for article (PubMed ID: 31855560)
1. Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells.
Zhao HJ; Jiang X; Hu LJ; Yang L; Deng LD; Wang YP; Ren ZP
J Mol Endocrinol; 2020 Feb; 64(2):103-113. PubMed ID: 31855560
[TBL] [Abstract][Full Text] [Related]
2. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway.
Zhao H; Wang L; Wei R; Xiu D; Tao M; Ke J; Liu Y; Yang J; Hong T
Diabetes Obes Metab; 2014 Sep; 16(9):850-60. PubMed ID: 24641303
[TBL] [Abstract][Full Text] [Related]
3. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.
Zhao H; Wei R; Wang L; Tian Q; Tao M; Ke J; Liu Y; Hou W; Zhang L; Yang J; Hong T
Am J Physiol Endocrinol Metab; 2014 Jun; 306(12):E1431-41. PubMed ID: 24801389
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4/ROS/VEGF pathway.
Liu ZZ; Duan XX; Yuan MC; Yu J; Hu X; Han X; Lan L; Liu BW; Wang Y; Qin JF
Life Sci; 2022 Apr; 294():120370. PubMed ID: 35124000
[TBL] [Abstract][Full Text] [Related]
6. Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells.
Torres C; Linares A; Alejandre MJ; Palomino-Morales RJ; Delgado JR; Perales S
Pancreas; 2016 Feb; 45(2):269-80. PubMed ID: 26495790
[TBL] [Abstract][Full Text] [Related]
7. Liraglutide ameliorates palmitate-induced oxidative injury in islet microvascular endothelial cells through GLP-1 receptor/PKA and GTPCH1/eNOS signaling pathways.
Le Y; Wei R; Yang K; Lang S; Gu L; Liu J; Hong T; Yang J
Peptides; 2020 Feb; 124():170212. PubMed ID: 31770577
[TBL] [Abstract][Full Text] [Related]
8. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving β-catenin.
Wu X; Li S; Xue P; Li Y
Exp Cell Res; 2017 Nov; 360(2):281-291. PubMed ID: 28919123
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R.
Li Z; Li S; Wang N; Xue P; Li Y
Biomed Pharmacother; 2020 Oct; 130():110523. PubMed ID: 32702632
[TBL] [Abstract][Full Text] [Related]
11. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.
Liu J; Ma J; Wu Z; Li W; Zhang D; Han L; Wang F; Reindl KM; Wu E; Ma Q
BMC Cancer; 2014 Sep; 14():686. PubMed ID: 25240403
[TBL] [Abstract][Full Text] [Related]
12. Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer.
Kanda R; Hiraike H; Wada-Hiraike O; Ichinose T; Nagasaka K; Sasajima Y; Ryo E; Fujii T; Osuga Y; Ayabe T
BMC Cancer; 2018 Jun; 18(1):657. PubMed ID: 29907137
[TBL] [Abstract][Full Text] [Related]
13. Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells.
Koehler JA; Drucker DJ
Diabetes; 2006 May; 55(5):1369-79. PubMed ID: 16644694
[TBL] [Abstract][Full Text] [Related]
14. Low‑intensity low‑frequency ultrasound enhances the chemosensitivity of gemcitabine‑resistant ASPC‑1 cells via PI3K/AKT/NF‑κB pathway‑mediated ABC transporters.
Qiu F; Chen J; Cao J; Diao F; Huang P
Oncol Rep; 2020 Sep; 44(3):1158-1168. PubMed ID: 32705228
[TBL] [Abstract][Full Text] [Related]
15. IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation.
Zhuang Z; Ju HQ; Aguilar M; Gocho T; Li H; Iida T; Lee H; Fan X; Zhou H; Ling J; Li Z; Fu J; Wu M; Li M; Melisi D; Iwakura Y; Xu K; Fleming JB; Chiao PJ
Clin Cancer Res; 2016 Mar; 22(6):1432-44. PubMed ID: 26500238
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein.
Zhou W; Shao W; Zhang Y; Liu D; Liu M; Jin T
Am J Physiol Endocrinol Metab; 2020 Sep; 319(3):E568-E578. PubMed ID: 32723174
[TBL] [Abstract][Full Text] [Related]
17. PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist.
Nakamura T; Ito T; Uchida M; Hijioka M; Igarashi H; Oono T; Kato M; Nakamura K; Suzuki K; Jensen RT; Takayanagi R
Lab Invest; 2014 Jan; 94(1):63-78. PubMed ID: 24217090
[TBL] [Abstract][Full Text] [Related]
18. Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R/Akt/GSK3β signaling.
Shu X; Zhang Y; Li M; Huang X; Yang Y; Zeng J; Zhao Y; Wang X; Zhang W; Ying Y
Neuropharmacology; 2019 Jul; 153():1-12. PubMed ID: 31015047
[TBL] [Abstract][Full Text] [Related]
19. Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression.
Shigeoka T; Nomiyama T; Kawanami T; Hamaguchi Y; Horikawa T; Tanaka T; Irie S; Motonaga R; Hamanoue N; Tanabe M; Nabeshima K; Tanaka M; Yanase T; Kawanami D
J Diabetes Investig; 2020 Sep; 11(5):1137-1149. PubMed ID: 32146725
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 receptor activation alleviates lipopolysaccharide-induced acute lung injury in mice via maintenance of endothelial barrier function.
Xu J; Wei G; Wang J; Zhu J; Yu M; Zeng X; Wang H; Xie W; Kong H
Lab Invest; 2019 Apr; 99(4):577-587. PubMed ID: 30659271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
